For the second year in a row, the London-based Times Higher Education ranked UC San Diego the world’s number one research university founded during the “golden age” of higher education development, in the two decades between 1945 and 1967—when higher education was characterized by rapid university expansion and increasing investment in research.
Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
Researchers at University of California San Diego School of Medicine report that a first-in-human phase I clinical trial in which neural stem cells were transplanted into participants with chronic spinal cord injuries produced measurable improvement in three of four subjects, with no serious adverse effects.
To begin to understand the field of plasmonics, picture the rich colors of stained glass windows in Gothic cathedrals; or, the pixelation of a digital photo on a laptop screen. In some way, shape or form these are plasmons on display. Basically, plasmons are traveling waves of rippling electrons that can be excited in plasmas, metals or semiconductors. They lie at the heart of plasmonics. In such systems, plasmons bunch up and spread out as a group, enhancing and manipulating electromagnetic energy and concentrating optical energy beyond the diffraction limit of light. But much of this energy in common materials is quickly lost, or dissipated, as heat. And, while plasmons have found commercial applications in chemical sensors (e.g., common drug-store pregnancy tests), they have not been applied more widely or ambitiously because of high dissipation, which has frustrated scientists—until now.
Engineers at the University of California San Diego have developed tiny ultrasound-powered robots that can swim through blood, removing harmful bacteria along with the toxins they produce. These proof-of-concept nanorobots could one day offer a safe and efficient way to detoxify and decontaminate biological fluids.
The race is on between new antibiotics and drug-resistant bacteria—and scientists are challenged to keep up. By 2050, according to a Wellcome Trust study, deaths from deadly infections will be more common than cancer deaths. Scientists report that currently antimicrobial resistance causes 23,000 deaths annually in the U.S.; 700,000 deaths worldwide. Better methods to treat bacterial infections are urgently needed. So researchers, including a University of California San Diego professor, are gaining ground by demonstrating the first example of an effective gene therapy for deadly bacterial infections.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
